CG Oncology Presents 41.8% Complete Response Rate at 24 Months for Cretostimogene
Bitget2026/11/06 13:19- CG Oncology reported cretostimogene achieved a 41.8% complete response rate at 24 months in Phase 3 BOND-003 Cohort C.
- The cohort’s complete response rate reached 75.5% at any time; 46.4% at 12 months.
- No grade 3 or higher treatment-related adverse events were reported for cretostimogene.
- BOND-003 Cohort P showed 80.4% high-grade event-free survival at nine months in patients with BCG-unresponsive papillary-only bladder cancer.
- Manufacturing capacity stands at 40,000–50,000 vials annually, with a tenfold scale-up underway to support future indications.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
